Smart Biotech Scientist | The CMC and Biomanufacturing Podcast for Bioprocess Development and Manufacturing Leaders

What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?
This conversation features Steve Oh, a leader in advanced bioprocessing, whose career has placed him at the intersection of stem cell biology, process engineering, and clinical translation. Steve Oh joins David Brühlmann to share how XT Thrive®—a next-generation cryopreservation solution drawing from nature’s antifreeze proteins—lets cells survive, thrive, and simplify manufacturing from the bench to the clinic.
Episode highlights:
Biological insights from Arctic fish and their translation into synthetic peptide chemistry for cell preservation (00:23)
The effect of ice crystal formation on cellular damage, and how XT Thrive® minimizes this compared to DMSO (05:32)
Simplified logistics: reduced risk of contamination, elimination of post-thaw wash steps, and implications for therapy delivery to remote locations (07:23)
Applicability beyond single cells—preserving organoids and potential implications for tissue engineering (09:50)
The ease of transitioning from DMSO to the new solution in established lab protocols (10:49)
Broader industry challenges: maintaining purity, process optimization, and reducing cost of goods in cell therapy manufacturing (12:03)
Promising innovations in rapid cell type differentiation and barriers to scaling transformative biotech (12:50)
The importance of supporting innovative therapies beyond short-term ROI (14:17)
Smart insight:
Next-generation cryopreservation solutions address more than just viability—they simplify transport, reduce costs, lower hands-on time, and help ensure therapy reaches patients in remote locations in optimal condition. As Steve Oh observes, these advances are critical for reducing the cost of goods, improving consistency, and enabling truly scalable cell therapy manufacturing.
If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation—transforming how life-saving cells are frozen, stored, and shipped.
Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen
This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.
Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.
Connect with Steve Oh:
Email: [email protected]
LinkedIn: www.linkedin.com/in/steve-oh-4946261/
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show

Arctic fish survive in waters that would freeze most life solid. Not because they tolerate ice, but because their biology prevents crystals from forming in the first place. That same principle, translated into synthetic peptide chemistry, is now showing performance data that DMSO cannot match. Part 2 is where the science becomes practical.
Steve Oh spent 22 years at Singapore's A*STAR accumulating 43 patents across stem cell bioprocessing, microcarrier technologies, and serum-free media. He now advises XTherma, where he has been stress-testing their DMSO-free cryopreservation solution across T cells, MSCs, organoids, and beyond. In Part 2, he brings the data.
Key topics discussed:
How antifreeze protein-inspired peptide chemistry reduces ice crystal size and protects cells during freezing and thawing (00:23)
T cell and MSC performance data comparing XT Thrive to DMSO and CryoStor CS10, including a 2.5-fold increase in cell yield on microcarriers post-thaw (02:23-05:00)
Why ice crystal formation causes more damage during thawing than freezing, and how XT Thrive addresses this (05:32)
Elimination of the post-thaw wash step and what that means for contamination risk and manufacturing simplicity (07:00)
Hold time extended to 24 hours and storage performance across 4°C, -80°C, and -196°C (08:01)
Applicability beyond single cells: organoids, islets, and potential implications for organ preservation (09:50)
How to transition from DMSO to XT Thrive: GMP grade, Drug Master File, same concentration, no protocol overhaul required (10:49)
Broader cell therapy challenges: differentiation time, cell population consistency, and cost of goods (12:03)
Smart insight:
The transition away from DMSO is more accessible than most scientists assume. XT Thrive is GMP-grade, carries a Drug Master File, and is used at the same 5-10% concentration as DMSO, making it a plug-and-play substitution for most cell types. The manufacturing implications go further: no wash step, extended hold times, and storage stability across all standard temperature ranges simplify both production workflows and cold-chain logistics to remote treatment sites.
If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation, transforming how life-saving cells are frozen, stored, and shipped.
Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen
This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.
Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.
Connect with Steve Oh:
Email: [email protected]
LinkedIn: www.linkedin.com/in/steve-oh-4946261/
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show

Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position.
In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade building a company on licensing proprietary microbial technology rather than selling fermentation capacity, he brings a distinctive vantage point on where the CDMO industry is headed and what it will take to stay relevant.
Here are some of the topics discussed:
The need for innovation to stay competitive against lower-cost regions, and why capacity-focused business models are running out of road (03:08)
How continuous manufacturing creates a competitive edge for CDMOs operating in high-cost regions (05:49)
Practical advice for piloting continuous processing, building partnerships, and taking calculated risks before competitors do (06:36)
The parallel universe of batch and continuous manufacturing, and how this duality will shape the industry over the next decade (08:24)
What scientists need to know before spinning out a technology company: customer focus, cash discipline, and why the team is everything (09:49)
Big pharma's return to in-house manufacturing and vertical supply chain integration, and why this creates opportunity for innovation-focused partners (12:12)
Smart insight: Technology excellence is necessary but not sufficient. Juergen's closing word was simply "don't be afraid" and it carried weight precisely because it was not a platitude. The companies that will matter in ten years are those that start the hard work of innovation now, before the window closes.
If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:
Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos
Connect with Juergen Mairhofer:
LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b
enGenes Biotech GmbH website: www.engenes.cc
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show

What if continuous microbial manufacturing wasn't a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?
Meet Juergen Mairhofer, CEO of enGenes Biotech GmbH and a scientist with a rare dual fluency in molecular biology and bioprocess engineering. He's not just optimizing at the margins. He's devised a proprietary E. coli platform that radically stabilizes genetic stability and splits cell growth from protein production. Instead of stretching out fermentation for a few more days, he's running continuous E. coli processes for up to 40 days; something most believed impossible.
Here's why this conversation is worth your notebook and a second listen:
Why the commodity CDMO model struggles with innovation and how enGenes Biotech's model aligns business incentives with process improvement (02:37)
Juergen Mairhofer's early experiences blending molecular biology and bioprocess engineering, and how a "DIY" mentality led to entrepreneurship (04:42)
Strategy behind developing a proprietary E. coli strain that decouples protein production from cell growth (10:01)
The benefits of continuous manufacturing: running up to 40-day E. coli processes, and how this compares to mammalian (CHO) systems (13:57)
Economic and operational advantages: reducing facility footprint, lowering CAPEX/OPEX, and the necessity for innovation in global competition (19:25)
How enGenes Biotech integrates upstream and downstream operations for fully end-to-end continuous production (17:50)
Specific technical challenges: managing genetic drift, sterility, equipment, and process modeling in continuous systems (21:10)
Smart insight: Technology excellence is the entry ticket, but it won't sell itself. The companies that will lead the next decade of bioprocessing are those willing to align their business model with process innovation, not just capacity utilization.
If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:
Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos
Connect with Juergen Mairhofer:
LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b
enGenes Biotech GmbH website: www.engenes.cc
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
One bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.
Support the show

For many biotech innovators, high-throughput screening platforms promise faster discoveries and streamlined workflows. Yet beneath the surface, the reality is more demanding, requiring hands-on expertise, careful assay design, and a sharp understanding of microbial physiology to avoid mistakes that become expensive to fix downstream.
David Brühlmann continues his conversation with Sebastian Blum, Market Development Manager in Europe at Beckman Coulter Life Sciences, who brings a practical, unvarnished perspective to high-throughput screening. Drawing on conversations with startups, pharma, and CDMOs, Sebastian digs into what separates "push-button" automation myths from hard-won bioprocess mastery. From evaluating technical fit to troubleshooting real-world applications, he advocates for a nuanced approach, one focused on fit-for-purpose tools and critical thinking over technology hype.
In this episode, we discuss:
Practical advice for startups considering systems like the BioLector XT Microbioreactor, including the need for technical expertise and tailored applications (02:34)
Scenarios where the BioLector XT Microbioreactor is the best fit (flexibility, multiple microorganisms, modular upgrades) (04:22)
The most common mistakes scientists make with screening technologies, and why specialized personnel are still essential (06:45)
How automation, robotics, and AI are shaping the future of early-stage bioprocess development, and why core engineering principles remain vital (08:14)
Tips for evaluating screening tool placement in your process and aligning technology with your application needs (11:13)
If you're making decisions about high-throughput screening platforms and want to avoid costly missteps before scale-up, this episode delivers the clarity you need.
Connect with Sebastian Blum:
LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3b
Beckman Coulter Life Sciences: www.beckman.com
Next step:
Need fast CMC guidance? → Get rapid CMC decision support here
Support the show